Publications by authors named "Marco Vignetti"

Claim this Profile
U
Understanding challenges and barriers to quality end-of-life care for patients with hematologic malignancies: a GIMEMA survey.
Leonardo Potenza, Fabio Efficace, Eleonora Borelli, Paola Fazi, Thomas Baldi, Marco Vignetti

Ann Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study.
Adriano Venditti, Michal Kicinski, Ernesta Audisio, Mario Luppi, Monia Lunghi, Marco Vignetti

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.
Fabio Efficace, Laura Cannella, Isabella Capodanno, Rosaria Sancetta, Veronica Porcu, Marco Vignetti

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.
Fabio Stagno, Rosalba Cucci, Giovanni Marsili, Fausto Castagnetti, Sara Galimberti, Marco Vignetti

Am J Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index.
Daniela Krepper, Francesco Sparano, Johannes M Giesinger, Gianluca Gaidano, Pasquale Niscola, Marco Vignetti

J Geriatr Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia.
Francesco Sparano, Maria Teresa Voso, Adriano Venditti, Johannes M Giesinger, Thomas Baldi, Marco Vignetti

BMJ Support Palliat Care· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.
Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, Cristina Papayannidis, Marco Cerrano, Marco Vignetti

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the economic burden of Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL).
Matteo Scortichini, Martina Paoletti, Angela Ragonese, Antonio Cuneo, Marco Vignetti

Glob Reg Health Technol Assess· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.
Davide Lazzarotto, Marco Cerrano, Cristina Papayannidis, Sabina Chiaretti, Federico Mosna, Marco Vignetti

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.
Massimo Breccia, Rosalba Cucci, Giovanni Marsili, Fausto Castagnetti, Sara Galimberti, Marco Vignetti

Clin Lymphoma Myeloma Leuk· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project.
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, Konstanze Döhner, Hartmut Döhner, Marco Vignetti

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.
Fabio Efficace, Francesco Sparano, Massimo Breccia, Corinna Greco, Paola Carluccio, Marco Vignetti

Ann Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice.
Monica Messina, Alfonso Piciocchi, Leonardo M Siena, Stefano Soddu, Francesco Buccisano, Marco Vignetti

EJHaem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.
Fabio Forghieri, Stefano Cordella, Francesco Marchesi, Federico Itri, Maria Ilaria Del Principe, Marco Vignetti

Ann Hematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
Fabio Efficace, Michal Kicinski, Corneel Coens, Stefan Suciu, Walter J F M van der Velden, Marco Vignetti

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.
Adriano Venditti, Alfonso Piciocchi, Anna Candoni, Valentina Arena, Raffaele Palmieri, Marco Vignetti

Blood Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy.
Davide Petruzzelli, Marco Vignetti, Stefania Trasarti, Paolo Sportoletti, Silvia Della Torre

Glob Reg Health Technol Assess· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients.
Alfonso Piciocchi, Marta Cipriani, Monica Messina, Giovanni Marconi, Valentina Arena, Marco Vignetti

EJHaem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System.
Francesco Sparano, Johannes M Giesinger, Gianluca Gaidano, Amelie Anota, Michele Cavo, Marco Vignetti

JCO Oncol Pract· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Marco Vignetti

Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.
Fabio Efficace, Wael Al Essa, Uwe Platzbecker, Pasquale Niscola, Giuseppe A Palumbo, Marco Vignetti

Hemasphere· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Francesca R Mauro, Irene Della Starza, Monica Messina, Gianluigi Reda, Livio Trentin, Marco Vignetti

Haematologica· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Francesco Mannelli, Paola Guglielmelli, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Marco Vignetti

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review.
Fabio Efficace, Laura Cannella, Francesco Sparano, Johannes M Giesinger, Marco Vignetti

Hemasphere· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphadenopathies before and during the Pandemic COVID-19: Increasing Incidence of Metastases from Solid Tumors.
Stefania Trasarti, Raffaele Troiano, Mario Biglietto, Silvia Sorella, Chiara Lisi, Marco Vignetti

J Clin Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis